Hydrochloric Acid → HCID 178478113, Verbindung
Reaktionsgleichung
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([CH2:14][NH:15][C:16]2[N:21]=[C:20]3[NH:22][N:23]=[C:24]([C:25]4[CH:30]=[CH:29][N:28]=[C:27]([NH:31][CH2:32][C:33]5[CH:38]=[CH:37][CH:36]=[C:35]([Cl:39])[CH:34]=5)[N:26]=4)[C:19]3=[CH:18][N:17]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.Cl>CCO>[Cl:39][C:35]1[CH:34]=[C:33]([CH:38]=[CH:37][CH:36]=1)[CH2:32][NH:31][C:27]1[N:26]=[C:25]([C:24]2[C:19]3[C:20](=[N:21][C:16]([NH:15][CH2:14][CH:11]4[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]4)=[N:17][CH:18]=3)[NH:22][N:23]=2)[CH:30]=[CH:29][N:28]=1Komponenten
4
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
To a solution of 4-({3-[2-(3-chloro-benzylamino)-pyrimidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.36 mmol) in EtOH (4 mL) was added conc. HCl (4 mL). The reaction mixture was stirred at room temperature for 15 hours. The solvent was then removed and the residue was purified by prep-HPLC to afford {3-[2-(3-chloro-benzylamino)-pyrimidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-piperidin-4-ylmethyl-amine; hydrochloride. (Yield 60 mg, 30.0%).